



FOR IMMEDIATE RELEASE

CONTACT INFORMATION:

Lauren Whaley, Jennings, 919-929-0225, lwhaley@jenningsco.com

Dr. Thomas Fischer to speak at National Hemophilia Foundation's 60th Annual Meeting

Research Triangle Park, N.C., November 12, 2008 – Dr. Thomas Fischer, the vice president and chief science officer at Entegriion, is scheduled to speak at the National Hemophilia Foundation's 60th Annual Meeting, in Denver, CO. This conference will be held November 13 - 15 and is the largest yearly gathering of the hemophilia community. Dr. Fischer will discuss the proven effectiveness of Stasilon® versus standard-care gauze dressings for hemophiliacs as it relates to controlling blood loss.

Dr. Fischer is the inventor of Entegriion's innovative hemostatic wound dressing, Stasilon®. Unlike absorbent cotton gauze, the combination of glass and bamboo used in the dressing's fibers trigger the body's natural mechanisms for hemorrhage control by rapidly constricting and clotting damaged blood vessels. Wounds become stabilized and blood loss is drastically reduced. The first application of the technology, Stasilon® - FR for first responders is cleared by the FDA for use by medical professionals under prescription and over-the-counter by consumers.

The National Hemophilia Foundation's annual meeting is an opportunity to celebrate 60 years of dedicated efforts in education, advocacy and research on behalf of people and families with bleeding disorders. Dr. Fischer will be amongst NHF staff and board members, chapter and association leaders and volunteers, renowned healthcare providers and industry representatives.

About the National Hemophilia Foundation

The National Hemophilia Foundation is dedicated to finding better treatments and cures for bleeding and clotting disorders and to preventing the complications of these disorders through education, advocacy and research. Established in 1948, the National Hemophilia Foundation has chapters throughout the country. Its programs and initiatives are made possible through the

generosity of individuals, corporations and foundations as well as through a cooperative agreement with the Centers for Disease Control and Prevention (CDC).

About Entegriion

Entegriion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation and associated tissue repair. The company is based in North Carolina's Research Triangle Park, and is the inventor of Stasilon™ – the hemostatic medical textile technology cleared by the FDA for use by prescription and also by consumers – from which multiple hemorrhage control products are being made.

Building upon technologies licensed from the University of North Carolina, Entegriion's portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. Entegriion has also developed proprietary techniques for drying plasma and other blood components to provide for long shelf life with rapid rehydration for emergent and clinical use. For more information, visit www.entegriion.com.

###